Royal Bank of Canada’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,462
| Closed | -$353K | – | 7877 |
|
|
2023
Q2 | $353K | Buy |
3,462
+1,511
| +77% | +$143K | ﹤0.01% | 4227 |
|
|
2023
Q1 | $177K | Sell |
1,951
-2,726
| -58% | -$160K | ﹤0.01% | 4742 |
|
|
2022
Q4 | $178K | Buy |
4,677
+3,848
| +464% | +$132K | ﹤0.01% | 4974 |
|
|
2022
Q3 | $20K | Buy |
829
+539
| +186% | +$14.9K | ﹤0.01% | 6156 |
|
|
2022
Q2 | $9K | Sell |
290
-1,418
| -83% | -$42.3K | ﹤0.01% | 6441 |
|
|
2022
Q1 | $56K | Sell |
1,708
-3,897
| -70% | -$116K | ﹤0.01% | 6013 |
|
|
2021
Q4 | $148K | Buy |
5,605
+2,568
| +85% | +$199K | ﹤0.01% | 5642 |
|
|
2021
Q3 | $305K | Buy |
3,037
+1,126
| +59% | +$132K | ﹤0.01% | 4763 |
|
|
2021
Q2 | $271K | Sell |
1,911
-12,756
| -87% | -$1.44M | ﹤0.01% | 4803 |
|
|
2021
Q1 | $1.46M | Buy |
14,667
+14,238
| +3,319% | +$1.66M | ﹤0.01% | 3269 |
|
|
2020
Q4 | $53K | Buy |
429
+204
| +91% | +$26.8K | ﹤0.01% | 5643 |
|
|
2020
Q3 | $22K | Sell |
225
-12,849
| -98% | -$1.61M | ﹤0.01% | 5670 |
|
|
2020
Q2 | $2.04M | Buy |
13,074
+6,035
| +86% | +$917K | ﹤0.01% | 2593 |
|
|
2020
Q1 | $1.02M | Buy |
7,039
+6,562
| +1,376% | +$1.27M | ﹤0.01% | 3022 |
|
|
2019
Q4 | $98K | Buy |
477
+277
| +139% | +$50.5K | ﹤0.01% | 5094 |
|
|
2019
Q3 | $16K | Sell |
200
-204
| -50% | -$17.3K | ﹤0.01% | 5610 |
|
|
2019
Q2 | $38K | Sell |
404
-150
| -27% | -$13K | ﹤0.01% | 5420 |
|
|
2019
Q1 | $47K | Buy |
554
+22
| +4% | +$1.83K | ﹤0.01% | 5197 |
|
|
2018
Q4 | $30K | Sell |
532
-337
| -39% | -$20.6K | ﹤0.01% | 5387 |
|
|
2018
Q3 | $71K | Buy |
869
+330
| +61% | +$23.3K | ﹤0.01% | 5055 |
|
|
2018
Q2 | $18K | Buy |
539
+438
| +434% | +$13.3K | ﹤0.01% | 5588 |
|
|
2018
Q1 | $2K | Sell |
101
-27
| -21% | -$695 | ﹤0.01% | 6141 |
|
|
2017
Q4 | $4K | Sell |
128
-1,003
| -89% | -$28K | ﹤0.01% | 6152 |
|
|
2017
Q3 | $35K | Buy |
1,131
+1,065
| +1,614% | +$32K | ﹤0.01% | 5633 |
|
|
2017
Q2 | $2K | Sell |
66
-129
| -66% | -$3.17K | ﹤0.01% | 6308 |
|
|
2017
Q1 | $4K | Buy |
195
+154
| +376% | +$3.8K | ﹤0.01% | 6302 |
|
|
2016
Q4 | $1K | Buy |
+41
| New | +$1.04K | ﹤0.01% | 6578 |
|
Other funds holding RETA
Royal Bank of Canada's RETA Position: Q3 2023 in Review
Royal Bank of Canada sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,462 shares — an estimated $353K sold.
Royal Bank of Canada first reported a position in RETA in Q4 2016 and held it in 27 quarters. The position peaked at $2.04M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Royal Bank of Canada reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Royal Bank of Canada sold 3,462 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $353K.
- Royal Bank of Canada first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 27 quarters.
- Royal Bank of Canada's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.04M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.